These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38933451)

  • 21. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    Powles T; Valderrama BP; Gupta S; Bedke J; Kikuchi E; Hoffman-Censits J; Iyer G; Vulsteke C; Park SH; Shin SJ; Castellano D; Fornarini G; Li JR; Gümüş M; Mar N; Loriot Y; Fléchon A; Duran I; Drakaki A; Narayanan S; Yu X; Gorla S; Homet Moreno B; van der Heijden MS;
    N Engl J Med; 2024 Mar; 390(10):875-888. PubMed ID: 38446675
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma.
    Rosenberg J; Sridhar SS; Zhang J; Smith D; Ruether D; Flaig TW; Baranda J; Lang J; Plimack ER; Sangha R; Heath EI; Merchan J; Quinn DI; Srinivas S; Milowsky M; Wu C; Gartner EM; Zuo P; Melhem-Bertrandt A; Petrylak DP
    J Clin Oncol; 2020 Apr; 38(10):1041-1049. PubMed ID: 32031899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
    Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Saruta M; Takahara K; Fujita K; Minami T; Adachi T; Hirasawa Y; Hashimoto T; Ohno Y; Uemura H; Shiroki R; Azuma H; Kimura T
    Int J Urol; 2024 Apr; 31(4):342-347. PubMed ID: 38113343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
    McGregor BA; Sonpavde GP; Kwak L; Regan MM; Gao X; Hvidsten H; Mantia CM; Wei XX; Berchuck JE; Berg SA; Ravi PK; Michaelson MD; Choueiri TK; Bellmunt J
    Ann Oncol; 2024 Jan; 35(1):91-97. PubMed ID: 37871703
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
    Maiorano BA; Catalano M; Maiello E; Roviello G
    Front Oncol; 2023; 13():1254906. PubMed ID: 37781180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
    Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
    N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin.
    Jain RK; Skelton WP; Zhang J
    Cancer Manag Res; 2020; 12():8379-8386. PubMed ID: 32982431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Managing potential adverse events during treatment with enfortumab vedotin + pembrolizumab in patients with advanced urothelial cancer.
    Brower B; McCoy A; Ahmad H; Eitman C; Bowman IA; Rembisz J; Milowsky MI
    Front Oncol; 2024; 14():1326715. PubMed ID: 38711854
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma.
    Adib E; El Zarif T; Jain RK; Skelton WP; Freeman D; Curran C; Akl E; Nassar AH; Ravi P; Mantia C; Kwiatkowski DJ; Choueiri TK; Sonpavde G
    BJUI Compass; 2022 Mar; 3(2):169-172. PubMed ID: 35224552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
    Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2
    Fiala O; Massari F; Basso U; Giannatempo P; Grande E; Buti S; Myint ZW; De Giorgi U; Pichler R; Grillone F; Ürün Y; Calabrò F; Bourlon MT; Galli L; Kanesvaran R; Roviello G; Kucharz J; Rizzo M; Park SH; Cerbone L; Seront E; Messina C; Molina-Cerrillo J; Santini D; Yano A; Incorvaia L; Catalano M; Pinto A; Formisano L; Soares A; Facchini G; Fornarini G; Poprach A; Rebuzzi SE; Nasso C; Spinelli GP; Angel M; Stellato M; Tural D; Aurilio G; Epstein I; Carrozza F; Monteiro FSM; Benedetti G; Büchler T; Ortega C; Zakopoulou R; Battelli N; Porta C; Bellmunt J; Gupta S; Santoni M
    Target Oncol; 2024 Nov; 19(6):905-915. PubMed ID: 39354179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma.
    Takahashi S; Uemura M; Kimura T; Kawasaki Y; Takamoto A; Yamaguchi A; Melhem-Bertrandt A; Gartner EM; Inoue T; Akazawa R; Kadokura T; Tanikawa T
    Invest New Drugs; 2020 Aug; 38(4):1056-1066. PubMed ID: 31444589
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study.
    Minato A; Furubayashi N; Nagata Y; Tomoda T; Masaoka H; Song Y; Hori Y; Kiyoshima K; Negishi T; Kuroiwa K; Seki N; Tomisaki I; Harada K; Nakamura M; Fujimoto N
    Curr Oncol; 2024 Feb; 31(2):862-871. PubMed ID: 38392058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. First experience in treating advanced urothelial cancer with enfortumab vedotin. Single-centre retrospective study of patients qualified for a rescue access procedure.
    Sikora-Kupis B; Domański P; Fortuniak W; Kruczyk B; Staneta S; Piętak M; Mydlak A; Demkow T; Dumnicka P; Kucharz J
    Contemp Oncol (Pozn); 2023; 27(4):224-229. PubMed ID: 38405211
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enfortumab vedotin following platinum-based chemotherapy and immune checkpoint inhibitors for advanced urothelial carcinoma: response, survival and safety analysis from a multicentre real-world Japanese cohort.
    Miyake M; Nishimura N; Oda Y; Miyamoto T; Ohmori C; Takamatsu N; Itami Y; Tachibana A; Matsumoto Y; Kiba K; Tomioka A; Yamamoto H; Okajima E; Masaomi K; Sakamoto K; Tomizawa M; Shimizu T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Fujimoto K;
    Jpn J Clin Oncol; 2024 Mar; 54(3):329-338. PubMed ID: 38061911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Pharmacology of the Antibody-Drug Conjugate Enfortumab Vedotin in Advanced Urothelial Carcinoma and Other Malignant Solid Tumors.
    Tang M; Garg A; Bonate PL; Rosenberg JE; Matsangou M; Kadokura T; Yamada A; Choules M; Pavese J; Nagata M; Tenmizu D; Koibuchi A; Heo N; Wang L; Wojtkowski T; Hanley WD; Poondru S
    Clin Pharmacokinet; 2024 Apr; 63(4):423-438. PubMed ID: 38609704
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review.
    Padua TC; Moschini M; Martini A; Pederzoli F; Nocera L; Marandino L; Raggi D; Briganti A; Montorsi F; Necchi A
    Urol Oncol; 2022 Oct; 40(10):413-423. PubMed ID: 35973928
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma.
    Van Sanden S; Youssef A; Baculea S; Stubbs K; Triantos S; Yuan Z; Daly C
    J Health Econ Outcomes Res; 2024; 11(2):49-57. PubMed ID: 39267886
    [No Abstract]   [Full Text] [Related]  

  • 40. Outcomes of metastatic urothelial carcinoma following discontinuation of enfortumab-vedotin.
    Curran C; Adib E; Kazakova V; Grivas P; Diamantopoulos LN; Alva AS; Su C; Jain RK; Tandon A; Necchi A; Marandino L; Plastini TM; Merchan JR; Sonpavde G
    Clin Genitourin Cancer; 2022 Feb; 20(1):11-16. PubMed ID: 34503934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.